Clinical trial discovery
Find Clinical Trials
Search studies by condition, treatment, location, eligibility, or trial identifier.
Showing 1–9 of 9 trials
Active filters
Clinical trials found
Published and searchable clinical trials
Searching for clinical trials...
NCT06712810
- Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm, Blood Protein Disorders, Bone Marrow Diseases, +87 more
- Locations
-
- Mayo Clinic in Arizona Scottsdale, Arizona, United States
- Mayo Clinic in Rochester Rochester, Minnesota, United States
NCT02332980
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +48 more
- Locations
-
- Mayo Clinic in Arizona Scottsdale, Arizona, United States
- Mayo Clinic in Rochester Rochester, Minnesota, United States
NCT04578600
- Conditions
- Chronic Disease, Disease Attributes, Hematologic Diseases, +39 more
- Locations
-
- University of California Davis Comprehensive Cancer Center Sacramento, California, United States
NCT00723099
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, +63 more
- Locations
-
- University of Colorado Hospital Aurora, Colorado, United States
- Colorado Blood Cancer Institute Denver, Colorado, United States
- LDS Hospital Salt Lake City, Utah, United States
- VA Puget Sound Health Care System Seattle, Washington, United States
Completed
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT02950220
- Conditions
- B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Blood Protein Disorders, Burkitt Lymphoma, +46 more
- Locations
-
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
NCT03277729
- Conditions
- Chronic Disease, Disease Attributes, Hematologic Diseases, +43 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
Active, Not Recruiting
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT01955499
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +21 more
- Locations
-
- University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
- University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada
Active, Not Recruiting
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
NCT03479268
- Conditions
- B-Cell Prolymphocytic Leukemia, Chronic Disease, Disease Attributes, +40 more
- Locations
-
- City of Hope Medical Center Duarte, California, United States
- Roswell Park Comprehensive Cancer Center Buffalo, New York, United States
Active, Not Recruiting
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
NCT03015896
- Conditions
- Blood Protein Disorders, Burkitt Lymphoma, Cardiovascular Diseases, +42 more
- Locations
-
- Emory University Atlanta, Georgia, United States
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States